Valuation: Pathfinder Cell Therapy, Inc.

Market Cap 2.07M 1.82M 1.69M 1.55M 2.92M 198M 2.96M 20.12M 7.86M 97.94M 7.76M 7.6M 338M P/E 2013
-5.48x
P/E 2014 -0.38x
Enterprise Value 7.03M 6.18M 5.75M 5.28M 9.91M 674M 10.04M 68.33M 26.69M 333M 26.37M 25.8M 1.15B EV / Sales 2013
246,023,185x
EV / Sales 2014 -
Free-Float
100%
Yield 2013 *
-
Yield 2014 -
Manager TitleAgeSince
Chief Executive Officer 80 22/09/2011
Director of Finance/CFO 64 28/09/2011
Change 5-day change 1-year change 3-year change Capi.($)
-4.71%-13.83% - - 667
-0.29%-0.96%-1.17%+10.70% 47.74B
-0.61%+4.26%+396.16%+647.20% 39.98B
0.00%+4.93%+11.81%+55.56% 36.23B
+2.48%+4.57%+7.05%-5.05% 35.59B
+0.62%+3.53%+5.41%+42.19% 27.91B
-0.17%+0.66% - - 16.71B
-2.00%+11.64%+31.71%+136.81% 16.45B
+0.57%-3.36%+2.90%+8.02% 13.21B
+1.82%+1.56%-9.75%-30.15% 12.93B
Average +0.66%+2.77%+55.52%+108.16% 27.42B
Weighted average by Cap. +1.36%+2.94%+74.11%+136.34%

Financials

2013 2014
Net sales 0.05 0.05 0.04 0.04 0.08 5.18 0.08 0.53 0.21 2.56 0.2 0.2 8.84 -
Net income -1.7M -1.5M -1.4M -1.28M -2.41M -164M -2.44M -16.58M -6.48M -80.74M -6.4M -6.26M -279M -1.39M -1.23M -1.14M -1.05M -1.97M -134M -1.99M -13.56M -5.3M -66.01M -5.23M -5.12M -228M
Net Debt 3.94M 3.47M 3.23M 2.96M 5.57M 378M 5.64M 38.37M 14.99M 187M 14.81M 14.49M 646M 4.96M 4.36M 4.06M 3.73M 7M 475M 7.09M 48.22M 18.83M 235M 18.61M 18.21M 811M
Logo Pathfinder Cell Therapy, Inc.
Pathfinder Cell Therapy, Inc. is a regenerative medicine company. The Company is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The Company is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The Company has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The Company has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.
Employees
-